Should Primary Hyperparathyroidism at Age Below 40 Years Always Lead to Search for MEN-1, Despite Presence of Other Plausible Explanations? Abstract #492

Introduction: A 30-year-old female patient with inherited osteogenesis imperfecta (OI) Type 1 was referred due to hypercalcaemia and suspicion of primary hyperparathyroidism (pHPT). She had serum ca2+ 1.56 mmol/L, serum parathyroid hormone 115 ng/ml (< 70), and pHPT was diagnosed, but no scan uptake. By exploratory neck surgery, all parathyroid glands were hyperplastic and 3 ½ parathyroid + thymus were removed. The HPT was hypothesised to be due to abnormal calcium metabolism from OI (J Endocrinol Invest 1999), although not described previously.
Aim(s): Screening for MEN1
Materials and methods: Years later a study on screening for mutations in the menin gene of all patients who had or had had pHPT found her positive (Trp341STOP). This incidental diagnosis of MEN1 had two consequences:
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Professor Ulla Feldt-Rasmussen
Keywords: MEN-1, screening, pHPT

To read results and conclusion, please login ...

Further abstracts you may be interested in

#442 Low Diagnostic Accuracy of Tumor Markers for the Annual Screening of Pancreatic Neuroendocrine Tumors in MEN-1 Patients
Introduction: The use of tumor markers for annual screening for pancreatic neuroendocrine tumors (pNET) in Multiple Endocrine Neoplasia type 1 (MEN-1) is debatable because of low-level evidence and high costs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD PhD Gerlof Valk
#403 Insulinomas in Children
Introduction: Insulinomas are extremely rare tumors in children and an uncommon first manifestation of MEN1 syndrome. Insulinomas are usually benign tumors with only a few reports of malignant cases in children.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Maria Melikian
Keywords: MEN-1
#1327 Is Screening of Young Asymptomatic MEN1 Patients Necessary?
Introduction: Recent clinical practice guidelines recommend that routine screening of MEN1 mutation carriers should start at the age of 5 years to detect MEN1-associated tumors which is controversial in the scientific community.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: MD Jerena Manoharan
Keywords: Screening, MEN1
#223 Management of Patients with Multiple Pancreatic Tumors
Introduction: MEN-1 syndrome is a rather rare disease. It is very complicated to manage this group of patients because of the multiple pancreatic lesions and high frequency of nesidioblastosis.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Ivan Vasiliev
#348 Management of Multiple Endocrine Neoplasia Type 1 in Patients with Pancreatic Neuroendocrine Tumors
Introduction: Screening for MEN-1 is an integral part of examination of patients with pNETs because revelation of this hereditary pathology radically influences tactics of treatment.
Conference:
Category: Basic
Presenting Author: Ivan Vasiliev
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team